Company news

Shanghai MicuRx Pharmaceutical Co., Ltd. news in 2025

Shanghai MicuRx Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Announcement on Transfer of Some of The Company's Wholly-owned Subsidiary Kerui Kaisi's Business To Four Wholly-owned Subsidiaries Including Kangyue Biology, etc.

November 17, 2025

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

November 7, 2025

Announcement on Voluntary Disclosure of the Issuance of Approval Notices for Supplementary Applications for Drugs and Supplementary Applications for Drug Clinical Trials

November 5, 2025

Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025

November 4, 2025

Report for Q3 2025

October 27, 2025

Notice on the 3rd Extraordinary General Meeting in 2025

October 22, 2025

Announcement on Purchasing Liability Insurance for Directors and Senior Management Members

October 15, 2025

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

October 9, 2025

Announcement on Adding Extraordinary Proposal Supplementary Notice of the 2nd Extraordinary General Meeting in 2025

September 24, 2025

Announcement on Absence of Financial Assistance or Compensation Provided to the Investors in the Current Private Placement, Either Directly or Through Interested Parties

September 22, 2025

Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025

September 5, 2025

Report on the Transfer Result of Shareholders' Inquiry and Indicative Announcement on Change in Equity of Shareholder with Reaching 5% Shares Exceeding Integer Multiple of 5% and 1%

September 4, 2025

Announcement on Voluntary Disclosure of the Approval of Marketing Registration for Contezolid API from New Additional Manufacturer

September 1, 2025

Indicative Announcement on Pricing for Shareholder Inquiry Transfer

August 22, 2025

Shareholder's Inquiry Transfer Plan

August 21, 2025

Announcement on Resignation and Appointment of Deputy General Manager

August 19, 2025

Announcement on Continued Use of Idle Raised Funds Used for Cash Management

August 5, 2025

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

July 17, 2025

Announcement on Change of Sponsor Representative

July 15, 2025

Notice on Convening the 1st Extraordinary General Meeting in 2025

July 1, 2025

Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual Report

June 27, 2025

Announcement on Resolution of the 2024 Annual General Meeting

June 5, 2025

Announcement on the Voluntary Disclosure of Acceptance of the New Drug Application for the Marketing Authorization of Contezolid Acefosamil Sodium for Injection

May 21, 2025

Announcement on Convening the Q1 2025 Performance Briefing

May 19, 2025

Announcement on the Resignation of Independent Directors

May 12, 2025

Report for Q1 2025

April 23, 2025

Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing

April 14, 2025

MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025

April 8, 2025

Announcement on Vesting Results in the 1st Vesting Period of Initial Grant in 2023 Restricted Stock Incentive Plan and Shares Listing

March 20, 2025

Special Report on Deposit and Use of Raised Funds in 2024

March 17, 2025

MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment

February 25, 2025

Announcement on Preliminary Earnings Estimate for 2024

February 14, 2025